Comparative study to evaluate efficacy and safety of topical alcaftadine 0.25% versus topical olopatadine 0.2% eye drops in patients with allergic conjunctivitis in a tertiary care teaching hospital, Haldwani

Neeraj Rajdan; Bhavana Srivastava; Govind Singh Titiyal; Shujauddin; Shailja Kapri

doi:10.18203/2319-2003.ijbcp20250002

Authors

Neeraj Rajdan Department of Pharmacology, Government Medical College, Haldwani, Uttarakhand, India
Bhavana Srivastava Department of Pharmacology, Government Medical College, Haldwani, Uttarakhand, India
Govind Singh Titiyal Department of Ophthalmology, Government Medical College, Haldwani, Uttarakhand, India
Shujauddin Department of Pharmacology, Government Medical College, Haldwani, Uttarakhand, India
Shailja Kapri Department of Ophthalmology, Government Medical College, Haldwani, Uttarakhand, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20250002

Keywords:

AC, Alcaftadine, Olopatadine

Abstract

Background: Ocular component is the most prominent and disabling feature of allergy leading to symptoms like itching and watering of eyes causing significant irritation^. Allergic conjunctivitis (AC) is one of the most common ocular conditions affecting adult and pediatric patients that requires treatment by ophthalmologists. AC and its debilitating symptoms like itching, watering of eyes and ropy discharge have interfered their day to day activities, difficulty in concentrating in work and has adversely affect the quality of life. Aim and objectives were to study and compare the efficacy and safety profile of topical alcaftadine versus topical o lopatadine eye drops in patient with AC. To compare efficacy of topical alcaftadine versus topical olopatadine eye drops, to observe adverse drug reaction of both eye drops.

Methods: A prospective, open labelled comparative hospital based study was conducted in the department of ophthalmology in collaboration with department of pharmacology GMC Haldwani, Uttarakhand. Patients with AC (n=120) were randomised into two groups: Alcaftadine 0.25% eye drop and olopatadine 0.2% eye drop once daily. Patients were assessed on the first day 2^nd week and 4^th week. Reduction in total severity score and efficacy was measured in both treatment groups. Safety was assessed by observing adverse drug reaction using WHO UMC Causality assessment scale and modified Hartwig Siegel’s severity scale.

Results: A trend in significant improvement in patients treated with alcaftadine eye drop in comparison to patients treated with olopatadine eye drop at both second week and fourth week follow up. No adverse effects were reported with either eye drops in both groups.

Conclusions: Alcaftadine eye drop showed higher efficacy than olopatadine eye drop in relieving signs and symptoms of AC. Both treatment groups were found to be safe and effective.

Metrics

Metrics Loading ...

References

Mortemousque B, Fauquert JL, Chiambaretta F, Demoly P, Helleboid L, Creuzot-Garcher C, et al. Conjunctival provocation test: recommendations. J Francais Ophtalmol. 2006;29(7):837-46. DOI: https://doi.org/10.1016/S0181-5512(06)73857-8

John LJ, Ahmed S, Anjum F, Kebab M, Mohammed N, Darwich H, et al. Prevalence of Allergies among University Students: A Study from Ajman, United Arab Emirates. ISRN Aller 2014;502052. DOI: https://doi.org/10.1155/2014/502052

Davies RJ, Rusznak C, Devalia JL. Why is allergy increasing? environmental factors. Clin Experiment Aller. 1998;28(6):8-14. DOI: https://doi.org/10.1046/j.1365-2222.1998.0280s6008.x

Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Anna Aller Asthma Immunol. 1999;82(3):296-305. DOI: https://doi.org/10.1016/S1081-1206(10)62612-9

Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy and asthma proceedings. 2007;28(4):393-7. DOI: https://doi.org/10.2500/aap.2007.28.3013

Leonardi A, Bogacka E, Fauquert JL, Kowalski ML, Groblewska A, Jedrzejczak-Czechowicz M, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012;67(11):1327-37. DOI: https://doi.org/10.1111/all.12009

Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Aller Clin Immunol. 2010;126(4):778-83. DOI: https://doi.org/10.1016/j.jaci.2010.06.050

Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D, et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Alle Immunol. 2008;19(2):110-24. DOI: https://doi.org/10.1111/j.1399-3038.2007.00601.x

Collum L, Kilmartin DJ. Acute Allergic Conjunctivitis. In: Abelson MB, editor. Allergic diseases of the eye. Philadelphia: WB. Saunders Co. 2000;108-32.

Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Archives of ophthalmology (Chicago, Ill: 1960). 1981;99(2):302-4. DOI: https://doi.org/10.1001/archopht.1981.03930010304018

Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Current opinion in allergy and clinical Immunol. 2005;5(5):437-40. DOI: https://doi.org/10.1097/01.all.0000183113.63311.11

Nakano Y, Takahashi Y, Ono R, Kurata Y, Kagawa Y, Kamei C. Role of histamine H(4) receptor in allergic conjunctivitis in mice. Europ J Pharmacol. 2009;608(1-3):71-5. DOI: https://doi.org/10.1016/j.ejphar.2009.02.035

Zampeli E, Thurmond RL, Tiligada E. The histamine H4 receptor antagonist JNJ7777120 induces increases in the histamine content of the rat conjunctiva. Inflammation Res. 2009;58(6):285-91. DOI: https://doi.org/10.1007/s00011-009-8245-4

Lastacaft® (alcaftadine ophthalmic solution) 0.25% [prescribing information]. Irvine, CA: Allergan plc. 2015. Available at: http://www.allergan.com/ assets/pdf/lastacaft_pi.pdf. Accessed on 10 November 2024.

Pataday® (olopatadine hydrochloride ophthalmic solution) 0.2%. Fort Worth, TX: Alcon a Novartis Company; 2010. Available at: http://ecatalog.alcon.com/pi/Pataday_ us_en.pdf. Accessed on 10 November 2024.

Patanol® (olopatadine hydrochloride ophthalmic solution) 0.1%. Fort Worth, TX: Alcon a Novartis Company; 2007. Available at: http://ecatalog.alcon.com/pi/Patanol_us_ en.pdf. Accessed on 10 November 2024.

Wade L, Bielory L, Rudner S. Ophthalmic antihistamines and H1-H4 receptors. Curr Opin Aller Clin Immunol. 2012;12(5):510-6. DOI: https://doi.org/10.1097/ACI.0b013e328357d3ba

Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocular Pharmacol Therapeut. 1996;12(4):389-400. DOI: https://doi.org/10.1089/jop.1996.12.389

Patanol® (olopatadine hydrochloride ophthalmic solution) 0.1%. Fort Worth, TX: Alcon a Novartis Company; 2007. Available at: http://ecatalog.alcon. com/pi/Patanol_us_ en.pdf. Accessed on 10 November 2024.

Mahvan TD, Buckley WA, Hornecker JR. Alcaftadine for the prevention of itching associated with allergic conjunctivitis. Ann Pharmacoth. 2012;46(7-8):1025-32. DOI: https://doi.org/10.1345/aph.1Q755

Namdar R, Valdez C. Alcaftadine: a topical antihistamine for use in allergic conjunctivitis. Drugs of today (Barcelona, Spain: 1998). 2011;47(12):883-90. DOI: https://doi.org/10.1358/dot.2011.47.12.1709243

Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychological Med. 2013;35(2):121-6. DOI: https://doi.org/10.4103/0253-7176.116232

Santos MS, Alves MR, Freitas D, Sousa LB, Wainsztein R, Kandelman S, et al. Ocular allergy Latin American consensus. Arquivos Brasileiros Oftalmologia. 2011;74(6):452-6. DOI: https://doi.org/10.1590/S0004-27492011000600016

Uchio E, Kimura R, Migita H, Kozawa M, Kadonosono K. Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefe's Arch Clin Experiment Ophthalmol. 2018;246(2):291-6. DOI: https://doi.org/10.1007/s00417-007-0697-z

Robles-Contreras A, Santacruz C, Ayala J, Bracamontes E, Godinez V, Estrada-Garcia I, et al. Allergic Conjunctivitis: An Immunological Point of View. Conjunctivitis-A Complex and Multifaceted Disorder. InTech. 2011. DOI: https://doi.org/10.5772/26470

Ackerman S, D'Ambrosio F, Jr, Greiner JV, Villanueva L, Ciolino JB, Hollander DA. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. J Asthma Allergy. 2013;6:43-52. DOI: https://doi.org/10.2147/JAA.S38671

Greiner JV, Edwards-Swanson K, Ingerman A. valuation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol (Auckland, N.Z.). 2011;5:87-93. DOI: https://doi.org/10.2147/OPTH.S15379